株式

株式会社モダリス 2020/8/3 東証マザーズへ上場

Tokyo, JP · 5 known investors

modalistx.com ↗

Modalis Therapeutics develops therapeutics using CRISPR gene-editing technology and provides its platform technology for drug development. It operates in the biotechnology sector.

Investors · 5

ME

Medical Incubator Japan K.K.Tokyo

NI

Nippon Venture CapitalTokyo · $1.5M – $269M

SH

Shinsei Capital PartnersTokyo

SM

SMBC Venture CapitalTokyo · $2.3M – $269Mvia Hiroya Ota · inferred

UT

UTokyo Innovation Platform Co. Ltd.Tokyo